{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:28:21Z","timestamp":1768796901168,"version":"3.49.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.canrad.2023.08.008","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T09:15:54Z","timestamp":1703322954000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4270-5370","authenticated-orcid":false,"given":"L.","family":"Ollivier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Debbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.-H.","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cailleteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mervoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Belkac\u00e9mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.08.008_bib0460","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0535","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0465","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0470","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0475","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0480","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0485","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0490","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0495","first-page":"CD007941","article-title":"Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma","author":"Bauer","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2023.08.008_bib0500","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/00016923109138214","article-title":"Notre m\u00e9thode de roentgenth\u00e9rapie de la lymphogranulomatose (Hodgkin)\u00a0: r\u00e9sultats \u00e9loign\u00e9s","volume":"os-12","author":"Gilbert","year":"1931","journal-title":"Acta Radiol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0505","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1359-6349(12)70019-8","article-title":"Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy","volume":"10","author":"Meijnders","year":"2012","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.canrad.2023.08.008_bib0510","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2023.08.008_bib0515","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0520","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0575","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2023.08.008_bib0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0580","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by (18F)-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2023.08.008_bib0585","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0550","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0590","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/HS9.0000000000000160","article-title":"Rituximab with involved field irradiation for early-stage nodal follicular lymphoma","volume":"2","author":"Herfarth","year":"2018","journal-title":"HemaSphere"},{"key":"10.1016\/j.canrad.2023.08.008_bib0595","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0600","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMoa042040","article-title":"ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma","volume":"352","author":"Reyes","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0605","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0610","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019\u00e9tude des lymphomes de l\u2019adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0615","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0620","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0560","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2\u00d72 randomized UNFOLDER trial of the DSHNHL\/GLA","volume":"36","author":"Pfreundschuh","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0625","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0630","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0635","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4Gy versus 24Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0640","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0555","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0645","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0650","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0655","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0660","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2019.07.011","article-title":"Transplantation in children and adolescents with acute lymphoblastic leukemia from a matched donor versus an HLA-identical sibling: is the outcome comparable? Results from the International BFM ALL SCT 2007 study","volume":"25","author":"Balduzzi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.canrad.2023.08.008_bib0665","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/bjh.15761","article-title":"Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: the NOPHO ALL2008 experience","volume":"184","author":"Ifversen","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0670","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5144\/1658-3876.2011.17","article-title":"Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis","volume":"4","author":"Gupta","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.canrad.2023.08.008_bib0675","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11912-018-0719-5","article-title":"Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia","volume":"20","author":"Lawitschka","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.canrad.2023.08.008_bib0680","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41409-020-0806-8","volume":"55","author":"Saglio","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.canrad.2023.08.008_bib0685","doi-asserted-by":"crossref","first-page":"774348","DOI":"10.3389\/fped.2021.774348","article-title":"Total body irradiation in haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia: review of the literature and future directions","volume":"9","author":"Hoeben","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.canrad.2023.08.008_bib0690","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bbmt.2015.10.016","article-title":"Implications and management of central nervous system involvement before allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.canrad.2023.08.008_bib0695","doi-asserted-by":"crossref","first-page":"e26928","DOI":"10.1002\/pbc.26928","article-title":"Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study","volume":"65","author":"Barredo","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.canrad.2023.08.008_bib0700","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2018.05.067","article-title":"Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Pinnix","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0705","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.2003.08.047","article-title":"CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials","volume":"21","author":"Clarke","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0710","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/cncr.20413","article-title":"The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation","volume":"101","author":"Quaranta","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2023.08.008_bib0715","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V93.7.2196","volume":"93","author":"Ringd\u00e9n","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2023.08.008_bib0720","first-page":"694","article-title":"Is veno-occlusive disease incidence influenced by the total-body irradiation technique?","volume":"171","author":"Belkac\u00e9mi","year":"1995","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0725","doi-asserted-by":"crossref","first-page":"708727","DOI":"10.3389\/fonc.2021.708727","article-title":"Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis of randomized controlled trials","volume":"11","author":"Song","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0730","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jtct.2022.06.018","article-title":"Low-dose total body irradiation added to fludarabine and busulfan reduced-intensity conditioning reduces graft failure in patients with myelofibrosis","volume":"28","author":"Freyer","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.canrad.2023.08.008_bib0735","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1748-717X-8-92","article-title":"Total body irradiation (TBI) using Helical Tomotherapy in children and young adults undergoing stem cell transplantation","volume":"8","author":"Gruen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0740","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/bmt.2010.237","article-title":"Clinical feasibility of TBI with helical tomotherapy","volume":"46","author":"Pe\u00f1agar\u00edcano","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.canrad.2023.08.008_bib0745","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1080\/07853890.2022.2125171","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study","volume":"54","author":"Konishi","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0750","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/S1470-2045(20)30342-9","article-title":"Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia","volume":"21","author":"Wong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0755","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0760","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00066-017-1154-5","article-title":"Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma: A prospective randomised study","volume":"193","author":"Rudzianskiene","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0765","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial","volume":"12","author":"Berenson","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0770","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-019-0187-7","article-title":"The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)","volume":"9","author":"Kyriakou","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.canrad.2023.08.008_bib0775","doi-asserted-by":"crossref","first-page":"447","DOI":"10.36076\/ppj.2011\/14\/447","article-title":"The use of vertebral augmentation and external beam radiation therapy in the multimodal management of malignant vertebral compression fractures","volume":"14","author":"Hirsch","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.canrad.2023.08.008_bib0780","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.1994.12.11.2345","article-title":"Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease","volume":"12","author":"Townsend","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0785","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0790","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rpor.2016.07.009","article-title":"Low dose palliative radiotherapy for refractory aggressive lymphoma","volume":"21","author":"Tanaka","year":"2016","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.canrad.2023.08.008_bib0795","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clml.2021.05.007","article-title":"Palliative radiotherapy for diffuse large B-cell lymphoma","volume":"21","author":"Wright","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.canrad.2023.08.008_bib0800","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2023.08.008_bib0805","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/mco.2021.2276","article-title":"Radiotherapy for symptom palliation of splenomegaly in patients with haematological malignancies","volume":"14","author":"Katano","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0810","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00066-011-2252-4","article-title":"Radiotherapy of splenomegaly: a palliative treatment option for a benign phenomenon in malignant diseases","volume":"187","author":"Kriz","year":"2011","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0815","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.prro.2011.02.010","article-title":"Radiation therapy for leukemia cutis","volume":"1","author":"Bakst","year":"2011","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0820","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00432-016-2338-6","article-title":"The effectiveness of radiotherapy for leukemia cutis","volume":"143","author":"Elsayad","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0825","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of radiation in extramedullary leukemia\/chloroma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Bakst","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0830","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0835","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0840","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.canrad.2023.08.008_bib0845","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell Therapy with axicabtagene ciloleucel in diffuse large B-Cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0850","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-Cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.492","article-title":"Don\u2019t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma","author":"Saifi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0860","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.canrad.2023.08.008_bib0865","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2023.08.008_bib0870","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijrobp.2010.02.024","article-title":"Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition","volume":"80","author":"Metwally","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0875","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijrobp.2005.06.004","volume":"64","author":"Girinsky","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0880","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0885","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0890","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.08.008_bib0895","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2013.04.030","article-title":"Incidence of second malignancies among patients treated with proton versus photon radiation","volume":"87","author":"Chung","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0900","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.3390\/cancers13153746","article-title":"Current situation of proton therapy for Hodgkin lymphoma: from expectations to evidence","volume":"13","author":"Loap","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.08.008_bib0905","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0910","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2023.08.008_bib0525","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.08.008_bib0530","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2023.08.008_bib0565","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2023.08.008_bib0570","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2018.04.071","article-title":"Total body irradiation: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"101","author":"Wong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823002421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:38:32Z","timestamp":1761136712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823002421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1278321823002421"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.08.008","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is oligometastatic disease an applicable and useful concept in haematologic malignancies? A narrative review of radiation therapy standards, modern techniques, and innovations","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}